Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model

Blood

Volumn 121, Issue 7, 2013, Pages 1188-1199

  Kubovcakova, Lucia ^a   Lundberg, Pontus ^a   Grisouard, Jean ^a   Hao Shen, Hui ^a   Romanet, Vincent ^b   Andraos, Rita ^b   Murakami, Masato ^b   Dirnhofer, Stephan ^c   Wagner, Kay Uwe ^d   Radimerski, Thomas ^b   Skoda, Radek C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; HYDROXYUREA; INC 424; JANUS KINASE 2; MESSENGER RNA; RUXOLITINIB; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; ERYTHROPOIESIS; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MOUSE; MYELOPROLIFERATIVE NEOPLASM; NEUTROPHIL; NONHUMAN; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPLEEN; SPLEEN SIZE; THROMBOCYTE; WEIGHT REDUCTION; WILD TYPE;

EID: 84874091669     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-415646     Document Type: Article

References (45)

1. James C, Ugo V, Le Couedic JP, et al. Aunique clonal JAK2 mutation leading to constitutive signalling causes polycythaemiavera. Nature. 2005; 434(7037):1144-1148. (Pubitemid 40663494)
2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365(9464):1054-1061. (Pubitemid 40386783)
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397. (Pubitemid 40544655)
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17): 1779-1790. (Pubitemid 40570926)
5. Van Etten RA, Koschmieder S, Delhommeau F, et al. The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica. 2011;96(4): 590-601.
6. Li J, Kent DG, Chen E, Green AR. Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis Model Mech. 2011;4(3):311-317.
7. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-3940.
8. Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10(2):127-140.
9. Tefferi A, Pardanani A. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Rev. 2011;25(5):229-237.
10. Krempler A, Qi Y, Triplett AA, Zhu J, Rui H, Wagner KU. Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. Genesis. 2004;40(1):52-57. (Pubitemid 39655118)
11. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science. 1995; 269(5229):1427-1429.
12. Gothert JR, Gustin SE, Hall MA, et al. In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis. Blood. 2005; 105(7):2724-2732. (Pubitemid 40446262)
13. de Boer J, Williams A, Skavdis G, et al. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. Eur J Immunol. 2003; 33(2):314-325. (Pubitemid 36267595)
14. Schaefer BC, Schaefer ML, Kappler JW, Marrack P, Kedl RM. Observation of antigen-dependent CD8+ T-cell/dendritic cell interactions in vivo. Cell Immunol. 2001;214(2):110-122. (Pubitemid 34499465)
15. Weigert O, Lane AA, Bird L, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med. 2012;209(2): 259-273.
16. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107(11):4274-4281. (Pubitemid 43801351)
17. Li J, Spensberger D, Ahn JS, et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood. 2010; 116(9):1528-1538.
18. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibro-sis. Blood. 2006;108(5):1652-1660. (Pubitemid 44316134)
19. Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F-positive myelopro-liferative disease. Cancer Res. 2006;66(23): 11156-11165. (Pubitemid 46009942)
20. Zaleskas VM, Krause DS, Lazarides K, et al. Molecular Pathogenesis and Therapy of Polycythe-mia Induced in Mice by JAK2 V617F. PLoS One. 2006;1:e18.
21. Shide K, Shimoda HK, Kumano T, et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia. 2008;22(1): 87-95.
22. Xing S, Wanting TH, Zhao W, et al. Transgenic expression of JAK2V617F causes myeloprolifera-tive disorders in mice. Blood. 2008;111(10):5109-5117.
23. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115(17):3589-3597.
24. Mullally A, Lane SW, Ball B, et al. Physiological Jak2V617F expression causes a lethal myelopro-liferative neoplasm with differential effects on he-matopoietic stem and progenitor cells. Cancer Cell. 2010;17(6):584-596.
25. Marty C, Lacout C, Martin A, et al. Myeloprolifera-tive neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood. 2010; 116(5):783-787.
26. Chen E, Beer PA, Godfrey AL, et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell. 2010;18(5):524-535.
27. Fleischman AG, Aichberger KJ, Luty SB, et al. TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011;118(24):6392-6398.
28. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
29. Girodon F, Schaeffer C, Cleyrat C, et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. Haematologica. 2008;93(11):1723-1727.
30. Ricksten A, Palmqvist L, Johansson P, Andreasson B. Rapid decline of JAK2V617F levels during hy-droxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haemato-logica. 2008;93(8):1260-1261.
31. Spanoudakis E, Bazdiara I, Kotsianidis I, et al. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients. Ann Hematol. 2009;88(7):629-632.
32. Besses C, Alvarez-Larran A, Martinez-Aviles L, et al. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients. Br J Haematol. 2011;152(4):413-419.
33. Larsen TS, Pallisgaard N, de Stricker K, Moller MB, Hasselbalch HC. Limited efficacy of hy-droxyurea in lowering of the JAK2 V617F allele burden. Hematology. 2009;14(1):11-15.
34. Antonioli E, Carobbio A, Pieri L, et al. Hy-droxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. Haemato-logica. 2010;95(8):1435-1438.
35. Zalcberg IR, Ayres-Silva J, de Azevedo AM, Solza C, Daumas A, Bonamino M. Hydroxyurea dose impacts hematologic parameters in polycy-themia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden. Haematologica. 2011;96(3):e18-e20.
36. Theocharides A, Passweg JR, Medinger M, et al. The allele burden of JAK2 mutations remains stable over several years in patients with my-eloproliferative disorders. Haematologica. 2008; 93(12):1890-1893.
37. Plo I, Nakatake M, Malivert L, et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood. 2008; 112(4):1402-1412.
38. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659-661. (Pubitemid 351348146)
39. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008;13(4):311-320. (Pubitemid 351446195)
40. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia. 2007;21(8):1658-1668. (Pubitemid 47086756)
41. Liu PC, Caulder E, Li J, et al. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity. Clin Cancer Res. 2009;15(22):6891-6900.
42. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclini-cal characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109-3117.
43. Baffert F, Regnier CH, De Pover A, et al. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol Cancer Ther. 2010;9(7):1945-1955.
44. Hart S, Goh KC, Novotny-Diermayr V, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia. 2011;25(11): 1751-1759.
45. Kirabo A, Park SO, Majumder A, et al. The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow. Neoplasia. 2011;13(11):1058-1068.